摘要
目的 探讨利用放射性核素示踪技术研究半乳糖抗小鼠CD3 单克隆抗体 (Gal Ant CD3McAb)作为原发性肝癌 (PLC)术后免疫治疗载体的可行性。方法 以半乳糖 (Gal)为原料 ,制得 2 亚氨基 2 甲氧乙基 1 硫代 β D 半乳糖苷 (IME) ,与抗小鼠CD3 单克隆抗体 (Ant CD3 McAb)共价偶联制得Gal Ant CD3 McAb ,再用1 3 1 I或1 2 5 I标记Gal Ant CD3 McAb和Ant CD3 McAb ,通过小鼠体内分布实验和家兔显像实验 ,对比研究两者肝化差异 ;将Gal Ant CD3 McAb与肿瘤浸润淋巴细胞 (TIL)联接制得Gal Ant CD3 McAb TIL ,研究其体外趋肝性和杀伤自体肿瘤细胞作用。结果 Gal Ant CD3 McAb具有明显的趋肝性 ,每克肝组织最大摄取率为注入量的 (5 9 0± 2 1) % ,是Ant CD3 McAb的 2倍以上 ;Gal Ant CD3 McAb TIL在体外有良好的趋肝性 ,且杀伤自体肿瘤细胞的作用极强。结论 Gal Ant
Objective To probe into the feasibility of galactosyl anti mouse CD 3 monoclonal antibody (Gal Ant CD 3 McAb) being used as carrier of immunotherapy after surgical operation of liver cancer Methods Gal Ant CD 3 McAb was prepared by the covalent coupling of anti mouse CD 3 monoclonal antibody (Ant CD 3 McAb) with a bifunctional reagent, 2 imino 2 methoxyethyl 1 thiogalactose After Gal Ant CD 3 McAb and Ant CD 3 McAb were labelled with 131 I or 125 I, the data of biodistribution in mice, and of imaging in rabbit were obtained After tumour infiltrating lymphocytes (TIL) and Gal Ant CD 3 McAb were coupled into Gal Ant CD 3 McAb TIL, its livertaxis and cytotoxic activity against autologous cancer cells were measured in vitro Results Gal Ant CD 3 McAb had remarkable livertaxis and its uptake in per gram liver was (59 0±2 1)% that was more than two fold higher than that of Ant CD 3 McAb Gal Ant CD 3 McAb TIL had an obvious livertaxis and cytotoxic activity against autologous cancer cells in vitro Conclusion Gal Ant CD 3 McAb can be used as the carrier of immunotherapy after surgical operation of liver cancer
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2000年第5期193-196,I007,共5页
Chinese Journal of Nuclear Medicine
基金
四川省科委科研基金资助项目
关键词
肝癌
放射免疫疗法
单克隆抗体
术后
实验研究
Liver neoplasms
Carcinoma
Radioimmunotherapy
Antibodies, monoclonal
Animals, laboratory
